Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 800 of 2529 entries
View as:

Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.

Phase: N/A Priority: Normal
NCT ID: NCT02670928 Org: User:
Start: 07/20/15 End: 04/06/17 Due: 04/06/18

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT02678312 Org: User:
Start: 11/03/16 End: 01/03/22 Due: 01/03/23

Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France

Phase: N/A Priority: Normal
NCT ID: NCT05964946 Org: User:
Start: 06/24/20 End: 07/29/22 Due: 07/29/23

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

Phase: N/A Priority: Normal
NCT ID: NCT00818571 Org: User:
Start: 12/31/08 End: - Due: -

A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02452268 Org: User:
Start: 05/08/17 End: 03/07/22 Due: 03/07/23

Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01824264 Org: User:
Start: 11/30/15 End: 11/30/16 Due: 11/30/17

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India

Phase: N/A Priority: Normal
NCT ID: NCT05020873 Org: User:
Start: 11/04/21 End: 08/31/23 Due: 08/31/24

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Phase: N/A Priority: Normal
NCT ID: NCT01541956 Org: User:
Start: 02/29/12 End: 12/31/13 Due: 12/31/14

Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials

Phase: N/A Priority: Normal
NCT ID: NCT06215287 Org: User:
Start: 01/12/24 End: 02/15/24 Due: 02/15/25

177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04689828 Org: User:
Start: 06/15/21 End: 09/30/25 Due: 09/30/26

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03504852 Org: User:
Start: 06/25/18 End: 07/15/20 Due: 07/15/21

DFT383 in Pediatric Participants With Nephropathic Cystinosis

Phase: N/A Priority: Normal
NCT ID: NCT06910813 Org: User:
Start: 06/02/25 End: 08/26/30 Due: 08/26/31

A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US

Phase: N/A Priority: Normal
NCT ID: NCT06952426 Org: User:
Start: 03/04/25 End: 06/30/25 Due: 06/30/26

Home Reported Outcomes in C3G Study

Phase: N/A Priority: Normal
NCT ID: NCT07029542 Org: User:
Start: 04/07/25 End: 04/30/26 Due: 04/30/27

An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT07029555 Org: User:
Start: 07/11/25 End: 05/16/28 Due: 05/16/29

Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04473040 Org: User:
Start: - End: - Due: -

Phase II BGG492 Capsule Extension for Partial Epilepsy

Phase: N/A Priority: Normal
NCT ID: NCT01338805 Org: User:
Start: 06/30/11 End: 07/31/12 Due: 07/31/13

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT04460729 Org: User:
Start: 11/11/20 End: 11/17/23 Due: 11/17/24

Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

Phase: N/A Priority: Normal
NCT ID: NCT03439046 Org: User:
Start: 02/02/18 End: 12/11/23 Due: 12/11/24

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Phase: N/A Priority: Normal
NCT ID: NCT01783444 Org: User:
Start: 02/26/13 End: 07/30/18 Due: 07/30/19

Managed Access Programs for LDK378, Ceritinib

Phase: N/A Priority: Normal
NCT ID: NCT05100134 Org: User:
Start: - End: - Due: -

Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT00267176 Org: User:
Start: 11/30/05 End: - Due: -

To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria

Phase: N/A Priority: Normal
NCT ID: NCT04675931 Org: User:
Start: 03/07/22 End: 09/26/25 Due: 09/26/26

Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT02740270 Org: User:
Start: 07/22/16 End: 03/03/20 Due: 03/03/21

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05888493 Org: User:
Start: 10/02/23 End: 01/18/31 Due: 01/18/32